A major focus of the recent meeting of the European Association for the Study of Diabetes focused on the risks and benefits of so-called incretin mimetics, a class of type 2 diabetes drugs that include glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The diabetes experts zeroed in on whether the drug increased the risk for cardiovascular events or pancreatic disease including acute pancreatitis and pancreatic cancer. The concerns were timely. GLP-1 and DPP-4 drugs are relatively new treatments for Type 2 diabetes. In 2005, Byetta became the first GLP-1 drug to be approved by the FDA. A year ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.